|Summary Togglebluebird bio and Inhibrx Announce Collaboration to Research, Develop and Commercialize CAR T Cell Immunotherapies||CAMBRIDGE, Mass. & SAN DIEGO --(BUSINESS WIRE)--Jan. 7, 2019-- bluebird bio, Inc . (Nasdaq: BLUE) and Inhibrx, Inc. (Inhibrx) today announced that they have entered into an exclusive license agreement to research, develop and commercialize chimeric antigen receptor (CAR) T cell therapies using|
|Summary Togglebluebird bio to Present at the 37th Annual J.P. Morgan Healthcare Conference||CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 3, 2019-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the 37 th Annual J.P. Morgan Healthcare Conference , Tuesday, January 8 , at 2:30 p.m. PT at the Westin St.|
The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. bluebird bio disavows any obligation to update the information contained in such press releases after the date of their issuance.